Nanoparticle COVID-19 vaccine elicits immune response in pre-clinical studies
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
List view / Grid view
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
The novel aryl hydrocarbon receptor (AHR) inhibiting drug slowed zika virus replication and prevented mouse foetuses malforming in infected mothers.
The novel nanoparticle delivered Mp6 peptide was able to inhibit thrombosis and reduce inflammation without increasing the risk of bleeding in mice after heart attacks.
The Brain Metastasis Cell Lines Panel compiles research from various international institutions on the numerous brain metastasis cell lines that have been developed, in hopes collaboration will expedite research and drug development.
Ophthalmology and engineering combine in a novel nanoparticle-delivered gene therapy approach to treating wet age-related macular degeneration.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
The vitamin K-based drug has a unique structure which researchers believe makes it effective in controlling even medication-resistant seizures.
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen.
Phoebe Chubb explores how digitalisation is shaking up the world of drug discovery and development by increasing productivity and reducing human error.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
A group of researchers has used locked nucleic acid gapmer antisense oligonucleotides to treat facioscapulohumeral muscular dystrophy in cells and mice.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
Biologics represent a growing class of drugs with indications in oncology, chronic inflammation, and autoimmune diseases.